Share Your Patent Quality Pet Peeves

07 January 2016 PharmaPatents Blog

The USPTO is inviting stakeholders to suggest topics for patent quality case studies. As explained in the December 21, 2015 Federal Register Notice, “the USPTO performs case studies to investigate specific quality-related issues,” such as the quality of “first Office actions on the merits.” Based on the results of a case study, the USPTO may “take action to remediate quality issues or to formulate best practices to further enhance quality.” Now, “[t]he USPTO … seeks to leverage the experience of its stakeholders to expand the use of case studies to additional quality-related topics.”

Patent Quality Submissions

The USPTO is asking for detailed suggestions of topics “affecting the USPTO’s
ability to effectively issue high-quality patents.” The USPTO particularly solicits submissions that:

  • propose a specific correlation or trend for study
  • suggest a methodology for investigation
  • explain how the results of the case study could be used to improve patent quality

While a submission may include concrete examples, it “should not contain information sufficient to identify any particular application, any particular examiner, or any particular art unit.”

The Federal Register Notice includes an example submission and details on how to submit suggested topics, which are requested by February 12, 2016.

Patent Quality Pet Peeves

Several topics come to mind that might be suitable for a case study:

  • Restriction practice in U.S. national stage applications: How frequently do U.S. examiners find lack of unity when the PCT examiner did not? Is the lack of unity finding justified under PCT rules?
  • Examination of Patent Prosecution Highway applications: How frequently do U.S. examiners reject claims over prior art already considered by the previous patent office? Are the rejections justified under U.S. law?
  • After-final practice: How frequently do examiners refuse to enter amendments presented under AFCP 2.0? Are the refusals justified, e.g., would it require more than “a limited amount of further consideration or search” to determine that the amendments overcame the pending rejections?

What are your patent quality pet peeves?

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Insights

A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Does The U.S. Need STRONGER Patents?
16 July 2019
PTAB Trial Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ